Structural basis of allosteric and synergistic activation of AMPK by furan-2-phosphonic derivative C2 binding

Christopher G. Langendorf (), Kevin R. W. Ngoei, John W. Scott, Naomi X. Y. Ling, Sam M. A. Issa, Michael A. Gorman, Michael W. Parker, Kei Sakamoto, Jonathan S. Oakhill and Bruce E. Kemp ()
Additional contact information
Christopher G. Langendorf: Protein Chemistry & Metabolism, St Vincent’s Institute of Medical Research, University of Melbourne
Kevin R. W. Ngoei: Protein Chemistry & Metabolism, St Vincent’s Institute of Medical Research, University of Melbourne
John W. Scott: Protein Chemistry & Metabolism, St Vincent’s Institute of Medical Research, University of Melbourne
Naomi X. Y. Ling: Metabolic Signaling Laboratory, St Vincent’s Institute of Medical Research, University of Melbourne
Sam M. A. Issa: Protein Chemistry & Metabolism, St Vincent’s Institute of Medical Research, University of Melbourne
Michael A. Gorman: ACRF Rational Drug Discovery Centre, St Vincent’s Institute of Medical Research, University of Melbourne
Michael W. Parker: ACRF Rational Drug Discovery Centre, St Vincent’s Institute of Medical Research, University of Melbourne
Kei Sakamoto: Nestlé Institute of Health Sciences SA
Jonathan S. Oakhill: Metabolic Signaling Laboratory, St Vincent’s Institute of Medical Research, University of Melbourne
Bruce E. Kemp: Protein Chemistry & Metabolism, St Vincent’s Institute of Medical Research, University of Melbourne

Nature Communications, 2016, vol. 7, issue 1, 1-8

Abstract: Abstract The metabolic stress-sensing enzyme AMP-activated protein kinase (AMPK) is responsible for regulating metabolism in response to energy supply and demand. Drugs that activate AMPK may be useful in the treatment of metabolic diseases including type 2 diabetes. We have determined the crystal structure of AMPK in complex with its activator 5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid (C2), revealing two C2-binding sites in the γ-subunit distinct from nucleotide sites. C2 acts synergistically with the drug A769662 to activate AMPK α1-containing complexes independent of upstream kinases. Our results show that dual drug therapies could be effective AMPK-targeting strategies to treat metabolic diseases.

Date: 2016
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms10912 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms10912

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms10912

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().